MedTrace Logo

Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis

NCT02476136 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 8800

Last updated 2016-09-27

No results posted yet for this study

Summary

Anxiety disorders are common disorders, which pose a major burden to society and the individual. An anxiety disorder may be treated with medication, in particular with antidepressants such as the selective serotonin reuptake inhibitors (SSRIs). However, much of what is known about antidepressants is derived from research in depression rather than anxiety. In recent years, researchers have found that antidepressants are more effective for severely depressed patients than they are for patients with milder symptoms. It is possible that a similar relationship between symptom severity and antidepressant efficacy exists for anxiety disorders, but there is currently little evidence available to answer this question. As antidepressants are frequently prescribed to patients with mild or moderate anxiety, a clear understanding of their effectiveness across the severity range is vital to inform treatment decisions. Therefore, the purpose of this meta-analysis is to examine whether initial symptom severity affects antidepressant efficacy for anxiety disorders.

Conditions

  • Anxiety Disorders
  • Panic Disorder
  • Obsessive-compulsive Disorder
  • Post-traumatic Stress Disorder
  • Generalized Anxiety Disorder
  • Social Anxiety Disorder

Interventions

DRUG

paroxetine, duloxetine, fluoxetine or venlafaxine

Sponsors & Collaborators

  • prof. Peter de Jonge

    lead OTHER

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-03-31
Completion
2016-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02476136 on ClinicalTrials.gov